Quote this publication Share Print

ALECENSA (alectinib), tyrosine kinase inhibitor

ONCOLOGY - New indication
Opinions on drugs - Posted on Nov 14 2018

Reason for request

Extension of indication

High clinical benefit and minor clinical added value compared to XALKORI as first line treatment of metastatic non-small cell lung cancer with ALK gene rearrangement.




  • ALECENSA has been granted marketing authorisation for the first-line treatment in monotherapy of adults suffering from advanced metastatic non-small cell lung cancer (NSCLC) with ALK rearrangement.

  • Its superiority over XALKORI(crizotinib) in terms of progression-free survival has been demonstrated, though it is impossible to draw any conclusions concerning overall survival due to the study methodology.

  • Its tolerance profile is comparable to crizotinib.

  • It is the preferred first-line treatment for this population.



Actual benefit



Improvement in actual benefit

IV (mineur)


Therapeutic use


Ce produit a fait l'objet d'un avis d'efficience rendu par la commission évaluation économique et santé publique le 10 juillet 2018.

See also